Roche Begins Phase II Trial for Alzheimer's Drug Targeting Neuroinflammation

Roche has commenced a new Phase II clinical trial, TARBELA-AD, to assess its investigational oral NLRP3 inhibitor, RG6434, for early symptomatic Alzheimer's disease. This trial represents a multi-pronged approach to targeting distinct biological mechanisms in Alzheimer's. Further data on another drug, trontinemab, will also be presented at the upcoming CTAD Congress.